NeoGenomics Reports Third Quarter 2026 Results October 28th, 2026|Business Wire| FORT MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics announced its third-quarter results for the period ended September 30, 2026. Please leave this field empty Subscribe to Our Newsletter We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information. Please check your Inbox or Spam folder now to confirm your subscription. Like this post? Share it! FacebookXLinkedInEmail Related Posts PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026 November 7th, 2026 | 0 Comments Aqtual Presents Data Linking Blood-Based Biomarkers to Tissue Biology and Treatment Response in Rheumatoid Arthritis November 7th, 2026 | 0 Comments New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System November 7th, 2026 | 0 Comments Lilly and Hims & Hers expand access to FDA-approved Lilly medicines November 6th, 2026 | 0 Comments Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting November 6th, 2026 | 0 Comments NeoGenomics to Participate in Upcoming Investor Conferences November 6th, 2026 | 0 Comments Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19 November 6th, 2026 | 0 Comments NHC Reports Third Quarter 2026 Earnings November 6th, 2026 | 0 Comments enGene to Participate in Upcoming Investor Conferences November 6th, 2026 | 0 Comments Enhanced Group to Report Third Quarter 2026 Financial Results November 6th, 2026 | 0 Comments Network Bio Announces Research Collaboration with a Leading Academic Medical Center to Build AI Models of Human Disease from Biospecimens November 6th, 2026 | 0 Comments Front Range Pharmaceuticals Receives FDA Fast Track Designation for FRP-003 in Long COVID November 6th, 2026 | 0 Comments